Latest news with #QHSLab
Yahoo
16-05-2025
- Business
- Yahoo
QHSLab, Inc. Signals Strategic Debt Restructuring to Strengthen Balance Sheet and Drive Growth
Company in Advanced Discussions to Restructure Convertible Debt and Unlock Shareholder Value Potential Agreement Expected to Improve Financial Flexibility and Reduce Dilution Pressure WEST PALM BEACH, FL, May 16, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the 'Company') (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, today announced that it is in advanced discussions with Catheter Precision, Inc. the current holder of its OID Notes previously held Mercer Street Global Opportunity Fund, LLC regarding a strategic restructuring intended to improve the Company's financial flexibility and long-term growth outlook. The restructuring is expected to significantly improve QHSLab's financial position by reducing near-term payment obligations, increasing the conversion price of existing debt instruments, and removing default-related overhang. The agreement—if finalized—would also introduce a payment-in-kind (PIK) interest option and extend the maturity of the notes, allowing the Company to redirect capital toward key growth initiatives. Expected Benefits of the Restructuring: Improved Balance Sheet Health: Restructuring expected to consolidate and extend existing obligations to reduce financial strain. Reduced Dilution Risk: Planned increase in conversion price aims to lift downward pressure on USAQ stock. 'We're working collaboratively with our new strategic partner to restructure our outstanding obligations in a way that both supports our growth and adds value for shareholders,' said Troy Grogan, President and CEO of QHSLab, Inc. 'This anticipated agreement, once completed, will represent a major step toward long-term financial strength, allowing us to execute more effectively on our digital health roadmap.' The Company expects to finalize the agreement and issue a formal announcement in the coming weeks. For more information about QHSLab and our healthcare solutions, please visit About QHSLab, Inc. QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients' vital signs and evaluate the effects of prescribed medicines and treatments on patients' health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.'s products and services are designed to help physicians improve patient monitoring and medical care while also increasing their revenues. Forward-Looking Statements Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as 'may,' 'could,' 'believes,' 'estimates,' 'targets,' 'expects,' or 'intends,' and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investor Relations Contact: Brett Maas, Managing Principal, Hayden IR, LLCbrett@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
QHSLab, Inc. Reports 32% Year-Over-Year Revenue Growth and Expanded Gross Margins in First Quarter 2025
Revenue increased 32% year-over-year to $645,419, driven by growth in ISP and Allergy Diagnostics Gross margin expanded to 66.6%, reflecting improved product mix and operational efficiencies WEST PALM BEACH, FL, May 15, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the 'Company') (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, today announced its financial results for the three months ended March 31, 2025. Financial Highlights for Q1 2025: Total revenue increased 32.1% to $645,419, compared to $488,587 in Q1 2024 Gross profit rose to $429,944, up from $286,158 in the prior-year period Gross margin expanded to 66.6%, from 58.6% in Q1 2024 The strong year-over-year growth was driven by a diversified revenue base including: A 28.0% increase in Integrated Service Program (ISP) revenue to $162,502 An 11.7% increase in Allergy Diagnostic Kit sales to $264,913 New revenue of $89,100 from the achievement of clinical study performance obligations Revenue Breakdown Q1 2025 Q1 2024 % Change Allergy Diagnostics $ 264,913 $ 237,066 +11.7 % ISP Services $ 162,502 $ 127,004 +28.0 % Immunotherapy $ 97,329 $ 86,325 +12.8 % Clinical Study $ 89,100 – New Subscriptions $ 9,285 $ 18,370 -49.5 % Shipping & Handling $ 9,970 $ 9,959 – Training & Other $ 12,320 $ 9,863 +24.9 % Total $ 645,419 $ 488,587 +32.1 % 'We're pleased to report strong top-line growth and a significant improvement in gross profitability for the first quarter,' said Troy Grogan, CEO of QHSLab. 'Our multi-pronged revenue model is beginning to show the structural advantages we anticipated. As our integrated clinical services and diagnostics continue gaining traction in primary care, we're focused on driving sustainable margin expansion and unlocking shareholder value.' The increase in gross margin reflects a favorable product mix, operational synergies across the company's core offerings, and increased revenue from high-margin services such as ISP and clinical research contracts. QHSLab expects continued variability in gross margin depending on timing and mix of new product introductions, customer profile, and negotiated pricing, but remains focused on achieving long-term profitability and scale. For more information about QHSLab and our healthcare solutions, please visit About QHSLab, Inc. QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients' vital signs and evaluate the effects of prescribed medicines and treatments on patients' health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.'s products and services are designed to help physicians improve patient monitoring and medical care while also increasing their revenues. Forward-Looking Statements Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as 'may,' 'could,' 'believes,' 'estimates,' 'targets,' 'expects,' or 'intends,' and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investor Relations Contact: Brett Maas, Managing Principal, Hayden IR, LLCbrett@ in to access your portfolio
Business Insider
13-05-2025
- Business
- Business Insider
Catheter Precision announces $1.5M private placement equity financing
Catheter Precision (VTAK) announced that it has entered into securities purchase agreements with institutional investors for a $1.5M private placement equity financing and the acquisition of certain promissory notes of QHSLab. Ladenburg Thalmann & Co. acted as exclusive placement agent for these transactions. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Associated Press
18-02-2025
- Business
- Associated Press
QHSLab, Inc. Reports Record Revenue Growth and Positive Net Income in Preliminary Q4 and FY 2024 Financial Results
Four consecutive quarters of year-over-year revenue growth underscore continued business momentum. Revenue surges 98% in Q4 2024 compared to Q4 2023, marking a milestone year for QHSLab. Operational efficiencies and strategic execution drive first profitable year. WEST PALM BEACH, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the 'Company') (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, today announced its preliminary, unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. For the full year 2024, the Company recorded record revenue growth, substantial gross margin improvements, its first-ever year of profitability on a GAAP basis and positive cash flow from operations, which enabled it to repay a portion of its outstanding debt strengthening its balance sheet. Financial Highlights: Fourth Quarter 2024 Preliminary Financial Results: Revenue surged 98% year-over-year to $625,981, compared to $315,020 in Q4 2023, marking four consecutive quarters of year-over-year revenue growth. Gross profit increased 117% to $412,154, with gross margin expanding to 65.8%, up from 60.3% in the prior-year quarter. Net income for Q4 2024 of $40,838, a significant improvement from a net loss of $86,627 in Q4 2023. Full-Year 2024 Preliminary Financial Results: Revenue grew 51% year-over-year, reaching $2.1 million compared to $1.4 million for the full-year 2023. Gross margin improved to 63.7%, reflecting an enhanced product mix and increased operational efficiencies. The Company recorded net income of $69,188 for 2024, compared to a net loss of $468,362 in 2023, underscoring QHSLab's strong financial momentum and commitment to profitable operations. Positive Cash Flow Generation: The Company reported net positive cash flow of $105,586, driven by $247,317 in cash flow from operations, reflecting strong business performance. This was partially offset by a $141,731 net cash outflow from financing activities, which includes debt repayments and other financial obligations. Continued Debt Reduction: The Company repaid $298,531 in loans, further strengthening its balance sheet and reducing financial liabilities, reinforcing its commitment to long-term financial stability. Management Commentary: 'These outstanding financial results reflect the continued execution of our strategic initiatives and the growing adoption of our digital medicine solutions,' said Troy Grogan, President and CEO of QHSLab. 'We are thrilled to report 98% revenue growth compared to Q4 2023, despite the fourth quarter historically being a lower performing quarter for healthcare companies due to the seasonal impact of patient volume. This growth demonstrates the strength of our business model and the resilience of our operations. Our improved gross margin and profitability highlight the effectiveness of our operational efficiencies and commitment to achieving and sustaining profitability. As we increase the number of physicians using QHSLab, our financial performance should continue to improve.' Audit Status and Future Outlook: The Company is currently finalizing its independent year-end audit in preparation for filing its Annual Report on Form 10-K prior to the 2024 SEC reporting deadline. While these financial results remain unaudited and are subject to change, management is confident in the reported numbers and expects only minor adjustments, if any. 'We look forward to sharing our fully audited results in the coming weeks and remain committed to delivering strong financial performance and value to our shareholders,' added Troy Grogan. 'With our continued expansion and operational efficiencies, we are excited about the future of QHSLab as we build on this momentum into 2025.' For more information about QHSLab and our healthcare solutions, please visit About QHSLab, Inc. QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients' vital signs and evaluate the effects of prescribed medicines and treatments on patients' health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.'s products and services are designed to help physicians improve patient monitoring and medical care while also increasing their revenues. Forward-Looking Statements Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as 'may,' 'could,' 'believes,' 'estimates,' 'targets,' 'expects,' or 'intends,' and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investor Relations Contact: 646-536-7331
